ClinicalTrials.Veeva

Menu
R

Rady Children's Hospital - San Diego | Hematology/Oncology Research Center, Peckham Center for Cancer and Blood Disorders

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cyclophosphamide
Vincristine Sulfate
Etoposide
Carboplatin
Doxorubicin Hydrochloride
Cisplatin
Methotrexate
Vincristine
Cytarabine
Prednisone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 179 total trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lympho...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepine...

Active, not recruiting
Prader-Willi Syndrome
Drug: Pitolisant oral tablets
Drug: Placebo oral tablet

This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that...

Active, not recruiting
Desmoid Fibromatosis
Unresectable Desmoid Fibromatosis
Drug: Nirogacestat
Procedure: Magnetic Resonance Imaging

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52...

Enrolling
Central Precocious Puberty
Drug: Debio 4326

This is a Phase I, multicenter, non-randomized, adaptive, open label, multiple ascending, intra-participant, dose-escalation study with an LTE part....

Active, not recruiting
Angelman Syndrome
Drug: RO7248824

This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-10...

Active, not recruiting
Atopic Dermatitis
Type 1 Hypersensitivity
Biological: STMC-103H
Biological: Placebo

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant gra...

Enrolling
Recurrent WHO Grade II Glioma
Glioblastoma
Drug: PARP Inhibitor BGB-290
Drug: Temozolomide

This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination w...

Enrolling
Solid Tumor
Drug: Cabozantinib
Drug: 13-cis-retinoic acid

The overall goal of this study is to determine the clinical benefit and safety of antiviral therapy for asymptomatic congenital cytomegalovirus (cCMV...

Active, not recruiting
SNHL
Cmv Congenital
Drug: Valganciclovir
Drug: Simple Syrup

This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion Angelman Syndrome (AS) aged 5-17 years (in...

Enrolling
Angelman Syndrome
Drug: 60 mg QD Alogabat
Drug: 40 mg QD Alogabat

This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in childr...

Active, not recruiting
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Drug: Vemurafenib

Trial sponsors

C
National Cancer Institute (NCI) logo
Incyte logo
Roche logo
University of California San Francisco (UCSF) logo
Pfizer logo
Baylor College of Medicine logo
Boehringer Ingelheim logo
Boston Children's Hospital logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems